Literature DB >> 25551723

Physicochemical properties of lomefloxacin, levofloxacin, and moxifloxacin relevant to the biopharmaceutics classification system.

Ewa Kłosińska-Szmurło, Monika Grudzień, Katarzyna Betlejewska-Kielak, Franciszek Pluciński, Joanna Biernacka, Aleksander Paweł Mazurek.   

Abstract

The aim of this investigation was to identify the impact of physicochemical properties of three fluoroquinolones (second, third, and fourth generation) on bioavailability in relation to the Biopharmaceutics Classification System (BCS) by in silico and in vitro methods. These properties were estimated by analyzing the electrostatic potential pattern and values of the free energy of solvation as well as the distribution coefficients and true partition coefficients of the studied compounds. This study was based on theoretical quantum-chemical methods and the in vitro shake-flask technique with two immiscible phases (n-octanol and phosphate buffer) as well as the experimental potentiometric method to estimate protonation macro- and micro-constants. Properties identified in the in vitro and in silico studies were similar and indicated high lipophilic properties of the studied molecules as well as their good solubility in a polar medium. It appears that both the theoretical methods and simple in vitro studies are useful tools for predicting the bioavailability of medicinal substances based on the BCS principles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25551723

Source DB:  PubMed          Journal:  Acta Chim Slov        ISSN: 1318-0207            Impact factor:   1.735


  8 in total

Review 1.  Cyclodextrin Inclusion Complexes with Antibiotics and Antibacterial Agents as Drug-Delivery Systems-A Pharmaceutical Perspective.

Authors:  Dariusz Boczar; Katarzyna Michalska
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

2.  The Influence of Lipid Matrix Composition on the Microenvironment of Levofloxacin in Liposomal Forms.

Authors:  I M Le-Deygen; A S Safronova; I M Kolmogorov; A A Skuredina; E V Kudryashova
Journal:  Russ J Bioorg Chem       Date:  2022-09-12       Impact factor: 1.254

3.  Synthesis and molecular docking of new N4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors.

Authors:  Hamada H H Mohammed; Doaa Mohamed Elroby Ali; Mohamed Badr; Ahmed G K Habib; Abobakr Mohamed Mahmoud; Sarah M Farhan; Shimaa Salah Hassan Abd El Gany; Soad A Mohamad; Alaa M Hayallah; Samar H Abbas; Gamal El-Din A Abuo-Rahma
Journal:  Mol Divers       Date:  2022-09-24       Impact factor: 3.364

4.  Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis.

Authors:  Ying An; Ya Wang; Shuang Wu; You-Hua Wang; Xing Qian; Zhen Li; Ying-Jun Fu; Yong Xie
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

Review 5.  Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.

Authors:  Ana R Millanao; Aracely Y Mora; Nicolás A Villagra; Sergio A Bucarey; Alejandro A Hidalgo
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

6.  AB-DB: Force-Field parameters, MD trajectories, QM-based data, and Descriptors of Antimicrobials.

Authors:  Silvia Gervasoni; Giuliano Malloci; Andrea Bosin; Attilio V Vargiu; Helen I Zgurskaya; Paolo Ruggerone
Journal:  Sci Data       Date:  2022-04-01       Impact factor: 6.444

Review 7.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

8.  Polyvinyl Chloride Modified Carbon Paste Electrodes for Sensitive Determination of Levofloxacin Drug in Serum, Urine, and Pharmaceutical Formulations.

Authors:  Fatehy M Abdel-Haleem; Sonia Mahmoud; Nour Eldin T Abdel-Ghani; Rasha Mohamed El Nashar; Mikhael Bechelany; Ahmed Barhoum
Journal:  Sensors (Basel)       Date:  2021-05-01       Impact factor: 3.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.